Findings that correlate Epstein-Barr virus (EBV) status and solid tumors could mean that future cancer treatment may be guided by a patient's EBV status.
David F. Penson, MD, MPH, answers Cancer Therapy Advisor's questions on the most key recent developments in prostate cancer management.
Patients with stage 4 lung cancer who quit smoking showed an improvement in overall survival, even if they quit before chemotherapy.
[Clinical Medicine Insights: Oncology] Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Breast Cancer Awareness Month Poll
Cancer Therapy Advisor Articles
- Will Epigenetic Drugs Improve Immunotherapy Outcomes?
- Preoperative Breast MRI Associated With Longer Wait Time to Surgery
- Quitting Smoking Prior to Chemo Linked to Improved Survival Rate in Stage 4 Lung Cancer
- PD-L1 May Predict Response to TKIs, VEGFs in Metastatic Clear Cell Renal Cell Carcinoma
- Hyper-CVAD Plus Ponatinib May Be Effective for Newly Diagnosed Ph+ Acute Leukemia
- Olaparib Plus Paclitaxel Active in Metastatic Gastric Cancer
- For Metastatic Gastric Cancer, Modified DCF Should Be First-Line Option
- Routine CT Scans for B-cell Lymphoma Patients in Complete Remission Not Recommended
- Viral MicroRNA Expression Linked to Worse Clinical Outcomes in Early Stage Malignancies
- Prognostic Markers for Survival in Mycosis Fundoides, Sézary Syndrome Identified
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|